Medicaid Inflation Rebates Would Apply To More Products Under Line Extension Proposal
Executive Summary
Proposed rule also addresses impact of copay ‘accumulator’ programs on reporting Medicaid best prices and lays out more stringent requirements for manufacturers to be able to exclude such assistance from calculations.
You may also be interested in...
New Combo Products Exempt From Medicaid Rule Applying Price Inflation Rebates To Line Extensions
CMS final rule narrows definition of new formulations potentially subject to much higher Medicaid rebates and delays effective date of provisions targeting health plan copay accumulator programs.
Medicaid’s Multiple Best Price Proposal Needs More Clarity Before Advancing, PhRMA Argues
Medicaid should go back to the drawing board on a key part of its proposal aimed at circumventing best price reporting obstacles to value-based purchasing.
What Is A ‘Line Extension’? Medicaid Tries Again With Sweeping Definition
In the latest reminder of how badly industry lost the argument over the value of incremental improvements in formulations, US is proposing enhanced Medicaid rebates on virtually all new formulations of existing brands.